Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2005 1
2006 1
2007 5
2008 24
2009 42
2010 36
2011 30
2012 40
2013 49
2014 56
2015 40
2016 21
2017 18
2018 8
2019 5
2020 7
2021 4
2022 2
2023 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Results by year

Filters applied: . Clear all
Page 1
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer.
Lerner SP, McConkey DJ, Tangen CM, Meeks JJ, Flaig TW, Hua X, Daneshmand S, Alva AS, Lucia MS, Theodorescu D, Goldkorn A, Milowsky MI, Choi W, Bangs R, Gustafson DL, Plets M, Thompson IM Jr. Lerner SP, et al. Clin Cancer Res. 2024 Jan 17;30(2):444-449. doi: 10.1158/1078-0432.CCR-23-0602. Clin Cancer Res. 2024. PMID: 37966367 Clinical Trial.
Genome-wide study of genetic polymorphisms predictive for outcome from first-line oxaliplatin-based chemotherapy in colorectal cancer patients.
Park HA, Edelmann D, Canzian F, Seibold P, Harrison TA, Hua X, Shi Q, Silverman A, Benner A, Macauda A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Int J Cancer. 2023 Nov 1;153(9):1623-1634. doi: 10.1002/ijc.34663. Epub 2023 Aug 4. Int J Cancer. 2023. PMID: 37539667
Predictive Polygenic Score for Outcome after First-Line Oxaliplatin-Based Chemotherapy in Colorectal Cancer Patients Using Supervised Principal Component Analysis.
Park HA, Edelmann D, Canzian F, Harrison TA, Hua X, Shi Q, Silverman A, Schneider M, Goldberg RM, Alberts SR, Hoffmeister M, Brenner H, Chan AT, Peters U, Newcomb PA, Chang-Claude J. Park HA, et al. Cancer Epidemiol Biomarkers Prev. 2022 Nov 2;31(11):2087-2091. doi: 10.1158/1055-9965.EPI-22-0320. Cancer Epidemiol Biomarkers Prev. 2022. PMID: 35984985 Free PMC article. Clinical Trial.
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Morgans AK, Chen YH, Jarrard DF, Carducci M, Liu G, Eisenberger M, Plimack ER, Bryce A, Garcia JA, Dreicer R, Vogelzang NJ, Picus J, Shevrin D, Hussain M, DiPaola RS, Cella D, Sweeney CJ; ECOG-ACRIN E3805 Investigators. Morgans AK, et al. Prostate. 2022 Sep;82(12):1176-1185. doi: 10.1002/pros.24369. Epub 2022 May 10. Prostate. 2022. PMID: 35538398 Free PMC article. Clinical Trial.
A polymorphism in the promoter of FRAS1 is a candidate SNP associated with metastatic prostate cancer.
Wang V, Geybels MS, Jordahl KM, Gerke T, Hamid A, Penney KL, Markt SC, Freedman M, Pomerantz M, Lee GM, Rana H, Börnigen D, Rebbeck TR, Huttenhower C, Eeles RA, Stanford JL, Consortium P, Berndt SI, Claessens F, Sørensen KD, Park JY, Vega A, Usmani N, Mucci L, Sweeney CJ. Wang V, et al. Prostate. 2021 Jul;81(10):683-693. doi: 10.1002/pros.24148. Epub 2021 May 6. Prostate. 2021. PMID: 33956343 Free PMC article.
Serum paraprotein persistence and size determine outcome in a cohort of patients with a modern definition of plasmacytoma with up to 19 years of follow up.
Manasanch EE, Kunacheewa C, Claussen CM, Lee HC, Thomas SK, Gunther J, Pinnix CC, Dabaja BS, Amini B, Alexanian R, Orlowski RZ, Dong W, Feng L, Weber DM. Manasanch EE, et al. Blood Cancer J. 2021 Feb 8;11(2):17. doi: 10.1038/s41408-021-00419-1. Blood Cancer J. 2021. PMID: 33563896 Free PMC article. No abstract available.
Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies.
Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Manasanch EE, et al. Br J Haematol. 2021 Feb;192(4):e115-e120. doi: 10.1111/bjh.17344. Epub 2021 Jan 24. Br J Haematol. 2021. PMID: 33486754 No abstract available.
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Usmani SZ, Hoering A, Ailawadhi S, Sexton R, Lipe B, Hita SF, Valent J, Rosenzweig M, Zonder JA, Dhodapkar M, Callander N, Zimmerman T, Voorhees PM, Durie B, Rajkumar SV, Richardson PG, Orlowski RZ; SWOG1211 Trial Investigators. Usmani SZ, et al. Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22. Lancet Haematol. 2021. PMID: 33357482 Free PMC article. Clinical Trial.
SARS-CoV-2 in multiple myeloma: initial observation and management.
Manasanch EE, Mulanovich V, Manzano JG, Gaeta MS, Becnel M, Kaufman GP, Lee HC, Amini B, Thomas SK, Iyer SP, Weber DM, Berkova Z, Flowers CR, Orlowski RZ, Patel KK. Manasanch EE, et al. Leuk Lymphoma. 2020 Nov;61(11):2763-2766. doi: 10.1080/10428194.2020.1780588. Epub 2020 Jun 17. Leuk Lymphoma. 2020. PMID: 33167721 Free PMC article. No abstract available.
334 results